Johnson & Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus. The health care products maker said Wednesday that the vaccine being developed by its Janssen Pharmaceutical Companies protects against an Ebola strain that is “highly similar” to the virus that has triggered the current outbreak in West Africa. Johnson & Johnson also plans to test whether its vaccine protects against the version causing the outbreak, which has killed more than 4,500 people.
Read more at Newsfeed.
